Navigation Links
NeurogesX Reports Third Quarter 2008 Results
Date:11/6/2008

NGX-4010 has the potential to receive a decision from the EMEA in the first half of 2009 and we anticipate the PDUFA date from the FDA for the NGX-4010 NDA to be in the second half of 2009. In preparation for the potential commercialization of NGX-4010 in Europe, we remain focused on securing a European commercialization partner. In the United States, while we remain confident that NGX-4010 for the management of pain associated with PHN can be launched effectively and efficiently using our own sales force targeting leading pain specialists, the current economic environment has prompted us to evaluate possible commercial partnerships for the potential U.S. launch of NGX-4010."

Third Quarter 2008 Financial Results

Total operating expenses for the third quarter of 2008 were approximately $6.3 million, including $373,000 of non-cash stock-based compensation expense, compared to approximately $9.5 million, including $389,000 of non-cash stock-based compensation expense, for the third quarter of 2007. The decrease in operating expenses was primarily attributed to lower costs associated with clinical studies of NGX-4010 as the Company had no large-scale clinical studies ongoing during the quarter. Partially offsetting lower clinical costs were increased internal regulatory expenses to support the submission of a new drug application for NGX-4010 in PHN with the FDA, increased expenses related to pre-commercialization activities for NGX-4010 and higher general and administrative expenses due to increased spending on general infrastructure and to support being a public company.

Net loss for the third quarter of 2008 was approximately $6.3 million, compared to a net loss of $9.2 million for the third quarter of 2007. Net loss per share attributable to common stockholders was $0.36 per share and $0.68 per share for the three months ended September 30, 2008 and 2007, respectively, based on weighted average shares outstanding of 17,538,886 and 13,429,471 res
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... a multi-arm Phase 1 study of MM-141, a bispecific ... in an oral session by Dr. Mansoor Saleh ... Research Annual Meeting in Philadelphia, PA. ... MM-141 as a monotherapy and in combination with everolimus ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... that Dr. Mark W. Sawicki , ... 3rd Annual BioLogistics Summit in San ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 PRC ... sponsor and exhibit at the ACRP 2015 Global Conference ... City, Utah. The Association of Clinical Research Professionals (ACRP) ... research conference solely focused on the conduct of clinical ... and development, and widely recognized industry certifications. , The ...
(Date:4/21/2015)... Mo. (PRWEB) April 21, 2015 A ... HOLLOWAY AMERICA is slated to discuss its custom fabrication ... present its reimagined website, which launched just prior to ... and Thurs. (April 21, 22 and 23) at the ... 12,000 representatives of the world’s largest and most innovative ...
Breaking Biology Technology:First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3
... AGREEMENT PROVIDES CORGENIX EXCLUSIVE WORLDWIDE RIGHTS TO ... FOR CARDIOVASCULAR INFLAMMATION, DENVER, March 18 ... a worldwide developer and marketer of,diagnostic test ... the Okayama,Prefecture Industrial Promotion Foundation covering new ...
... 18 Visionsense Corp. announces,FDA 510(k) Clearance ... Vision,System. The system is based on a ... targeting Minimal Invasive,laparoscopic and endoscopic Surgery (MIS)., ... enhances MIS surgical,procedures that are under served ...
... 18 /PRNewswire/ - Aegera Therapeutics announced today,the ... trial for AEG33773, a,novel, orally bioavailable small ... diabetic neuropathy. The Phase I study will ... AEG33773 using a randomized,double blind, placebo controlled, ...
Cached Biology Technology:Corgenix Signs Technology Licensing Agreement With Japanese Government 2Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... virus (HCV) are at an increased risk of developing ... a study published in the May 8, 2007, issue ... Researchers from the National Cancer Institute (NCI), part of ... Medicine, found that HCV infection increased the risk of ...
... certain neurodegenerative diseases, such as mad cow disease or ... of infectious protein called a prion. Remarkably, in recent ... beneficial roles in biology, and prions even may act ... , But although prions have received a great deal ...
... central Catalonia, is so delicate that experts cannot get physically ... the years since the tracks were discovered they have been ... weathered and eroding at a rapid rate. , To ... near-vertical rock faces. , Palaeontologists feared the tracks could ...
Cached Biology News:Risk of lymphoma increases with hepatitis C virus infection 2Scientists identify prion's infectious secret 2Scientists identify prion's infectious secret 3Diminishing dinosaur steps saved by laser and laptop 2Diminishing dinosaur steps saved by laser and laptop 3
Request Info...
ANTI STENOTROPHOMONAS MALTOPHILIA...
... Phoretix 2D, Expression and Evolution supports data ... gel analysis studies in determining differential protein ... component Oracle data base plug ... client software). Supports advanced statistical ...
Request Info...
Biology Products: